Bourgeon Capital Management LLC Has $124,000 Stake in Dicerna Pharmaceuticals, Inc. (DRNA)

Bourgeon Capital Management LLC increased its position in Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) by 188.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 39,000 shares of the biopharmaceutical company’s stock after buying an additional 25,500 shares during the period. Bourgeon Capital Management LLC’s holdings in Dicerna Pharmaceuticals were worth $124,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in DRNA. Sabby Management LLC increased its position in shares of Dicerna Pharmaceuticals by 100.0% in the first quarter. Sabby Management LLC now owns 200,000 shares of the biopharmaceutical company’s stock worth $680,000 after buying an additional 100,000 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Dicerna Pharmaceuticals by 26.1% in the fourth quarter. Renaissance Technologies LLC now owns 408,682 shares of the biopharmaceutical company’s stock worth $1,177,000 after buying an additional 84,682 shares in the last quarter. Paloma Partners Management Co increased its position in shares of Dicerna Pharmaceuticals by 49.7% in the first quarter. Paloma Partners Management Co now owns 160,000 shares of the biopharmaceutical company’s stock worth $544,000 after buying an additional 53,131 shares in the last quarter. UBS Group AG increased its position in shares of Dicerna Pharmaceuticals by 0.6% in the first quarter. UBS Group AG now owns 284,645 shares of the biopharmaceutical company’s stock worth $968,000 after buying an additional 1,599 shares in the last quarter. Finally, Palo Alto Investors LLC increased its position in shares of Dicerna Pharmaceuticals by 204.2% in the first quarter. Palo Alto Investors LLC now owns 481,519 shares of the biopharmaceutical company’s stock worth $1,637,000 after buying an additional 323,240 shares in the last quarter. 55.84% of the stock is owned by institutional investors and hedge funds.

Shares of Dicerna Pharmaceuticals, Inc. (NASDAQ DRNA) opened at 3.26 on Friday. The stock’s market cap is $67.95 million. Dicerna Pharmaceuticals, Inc. has a 1-year low of $2.42 and a 1-year high of $6.10. The company’s 50-day moving average price is $3.47 and its 200 day moving average price is $3.10.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by $0.54. Dicerna Pharmaceuticals had a negative return on equity of 140.08% and a negative net margin of 8,474.12%. The firm had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.08 million. During the same period in the prior year, the business earned ($0.75) EPS. The company’s quarterly revenue was up 2400.0% on a year-over-year basis. Equities analysts forecast that Dicerna Pharmaceuticals, Inc. will post ($2.31) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Bourgeon Capital Management LLC Has $124,000 Stake in Dicerna Pharmaceuticals, Inc. (DRNA)” was posted by Stock Observer and is the sole property of of Stock Observer. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.thestockobserver.com/2017/08/12/bourgeon-capital-management-llc-has-124000-stake-in-dicerna-pharmaceuticals-inc-drna.html.

Several research firms recently weighed in on DRNA. ValuEngine upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, July 22nd. HC Wainwright restated a “buy” rating and set a $5.00 target price on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 23rd. Zacks Investment Research upgraded Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, May 16th. Finally, Cowen and Company restated a “buy” rating on shares of Dicerna Pharmaceuticals in a research note on Tuesday, May 9th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $5.88.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Want to see what other hedge funds are holding DRNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA).

Institutional Ownership by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply